172 related articles for article (PubMed ID: 16413384)
21. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
22. Recombinant bispecific antibodies for cancer therapy.
Kontermann RE
Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
[TBL] [Abstract][Full Text] [Related]
23. Bispecific antibodies for polyclonal T-cell engagement.
Baeuerle PA; Kufer P; Lutterbüse R
Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
[TBL] [Abstract][Full Text] [Related]
24. Retargeting T cells and immune effector cells with bispecific antibodies.
Lum LG; Davol PA
Cancer Chemother Biol Response Modif; 2005; 22():273-91. PubMed ID: 16110617
[TBL] [Abstract][Full Text] [Related]
25. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
[TBL] [Abstract][Full Text] [Related]
26. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
27. Bispecific antibodies as novel bioconjugates.
Cao Y; Suresh MR
Bioconjug Chem; 1998; 9(6):635-44. PubMed ID: 9815155
[TBL] [Abstract][Full Text] [Related]
28. Bispecific Antibody Armed T Cells to Target Cancer Cells.
Thakur A; Lum LG; Mittal S
Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
[TBL] [Abstract][Full Text] [Related]
29. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
Deyev SM; Lebedenko EN
Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
[TBL] [Abstract][Full Text] [Related]
30. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
[TBL] [Abstract][Full Text] [Related]
31. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
32. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
33. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal and bispecific antibodies as novel therapeutics.
Booy EP; Johar D; Maddika S; Pirzada H; Sahib MM; Gehrke I; Loewen S; Louis SF; Kadkhoda K; Mowat M; Los M
Arch Immunol Ther Exp (Warsz); 2006; 54(2):85-101. PubMed ID: 16648969
[TBL] [Abstract][Full Text] [Related]
35. Bispecific antibodies in cancer immunotherapy.
Rader C
Curr Opin Biotechnol; 2020 Oct; 65():9-16. PubMed ID: 31841859
[TBL] [Abstract][Full Text] [Related]
36. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.
Herrmann T; Grosse-Hovest L; Otz T; Krammer PH; Rammensee HG; Jung G
Cancer Res; 2008 Feb; 68(4):1221-7. PubMed ID: 18281499
[TBL] [Abstract][Full Text] [Related]
37. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
[TBL] [Abstract][Full Text] [Related]
38. Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone.
Marvin JS; Zhu Z
Curr Opin Drug Discov Devel; 2006 Mar; 9(2):184-93. PubMed ID: 16566289
[TBL] [Abstract][Full Text] [Related]
39. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
[TBL] [Abstract][Full Text] [Related]
40. Comments on the Fourth International Conference on Bispecific Antibodies and Cellular Cytotoxicity, Duck Key, Florida, March 1-5, 1995.
Fanger MW; Ball ED; Drakeman DL
J Hematother; 1995 Oct; 4(5):345-9. PubMed ID: 8581367
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]